MondegarAI
DAFNA Capital Management LLC

Q2 2025 · 13F-HR

DAFNA Capital Management LLCholdings as filed

Filed 2025-08-14 · accession 0001389932-25-000011

$362.3M
Reported value
76
Positions
2025-06-30
Period end
View analyzed profile →PRO

The Brief · DAFNA Capital Management LLC · Q2 2025

AI · grounded in 13F

DAFNA Capital Management LLC established a new position in the SPDR S&P BIOTECH ETF XBI valued at $34.46M. The fund also initiated new stakes in STEREOTAXIS INC STXS for $29M and REVOLUTION MEDICINES INC RVMD for $24.91M. Additional new positions include BLUEPRINT MEDICINES CORP 2655787D and MERUS BV 2GH.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
78464A870XBISPDR S&P BIOTECH ETF$34.5M9.51%415,505CommonSOLE
85916J409STXSSTEREOTAXIS INC$29.0M8.01%13,680,554CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$24.9M6.88%677,176CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$21.6M5.97%168,763CommonSOLE
N5749R1002GHMERUS BV$21.0M5.79%398,804CommonSOLE
04963C209ATRCATRICURE INC$19.4M5.36%592,273CommonSOLE
23282W605CYTKCYTOKINETICS INC$13.2M3.63%398,100CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$13.0M3.59%619,090CommonSOLE
464287556IBBISHARES NASDAQ BIOTECH INDX$13.0M3.58%102,500CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$12.5M3.46%72,677CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$9.0M2.49%287,939CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$8.9M2.45%70,615CommonSOLE
05463X106AXGNAXOGEN INC$8.0M2.22%741,782CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$6.6M1.82%581,757CommonSOLE
252131107DXCMDEXCOM INC$5.7M1.58%65,552CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$5.7M1.58%879,163CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$5.7M1.57%501,972CommonSOLE
875372203TNDMTANDEM DIABETES CARE INC$5.5M1.51%294,208CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$5.1M1.41%627,626CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$5.1M1.41%543,602CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$5.0M1.39%371,523CommonSOLE
04351PAD3ASND 2.25 04/01/28ASCENDIS PHARMA A/S$5.0M1.38%4,000,000CommonSOLE
M96088105URGNUROGEN PHARMA LTD$4.8M1.32%349,515CommonSOLE
45780L104INGNINOGEN INC$4.3M1.18%605,625CommonSOLE
36315X101LKFTGALAPAGOS NV$3.6M1.01%130,175CommonSOLE
G1110E107BHVNBIOHAVEN LTD$3.3M0.92%235,235CommonSOLE
N71542109PRQRPROQR THERAPEUTICS N V$3.2M0.88%1,567,561CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$3.1M0.86%238,140CommonSOLE
45784P101PODDINSULET CORP$3.1M0.86%9,900CommonSOLE
45258J102IMVTIMMUNOVANT INC$3.1M0.85%191,493CommonSOLE
G01767105ALKSALKERMES PLC$3.0M0.82%103,748CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$2.9M0.81%317,001CommonSOLE
872381108TELATELA BIO INC$2.8M0.77%1,441,029CommonSOLE
50127T109KURAKURA ONCOLOGY INC$2.7M0.74%463,368CommonSOLE
24823R105DNLIDENALI THERAPEUTICS INC$2.4M0.65%168,500CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$2.3M0.63%811,046CommonSOLE
016255101ALGNALIGN TECHNOLOGY INC$2.1M0.57%11,000CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$2.0M0.54%218,255CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$1.7M0.48%324,775CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$1.7M0.48%130,316CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$1.7M0.47%64,516CommonSOLE
004397105ARAYACCURAY INC$1.7M0.46%1,222,358CommonSOLE
10501L106BWAYBRAINSWAY LTD$1.7M0.46%127,151CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$1.6M0.43%1,380,118CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$1.5M0.42%378,083CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$1.4M0.39%300,452CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$1.4M0.39%140,847CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$1.4M0.38%135,271CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$1.4M0.38%526,660CommonSOLE
N44445109IMTXIMMATICS NV$1.3M0.36%245,000CommonSOLE
014442107ALECALECTOR INC$1.3M0.35%912,928CommonSOLE
M68830112MDWDMEDIWOUND LTD$1.2M0.34%64,479CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$1.2M0.34%59,000CommonSOLE
09203E105BDTXBLACK DIAMOND THERAPEUTICS I$1.2M0.32%471,000CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$1.1M0.30%371,434CommonSOLE
92941V308VYNEVYNE THERAPEUTICS INC$1.0M0.29%636,103CommonSOLE
38341P102GOSSGOSSAMER BIO INC$1.0M0.29%849,921CommonSOLE
697947109PVLAPALVELLA THERAPEUTICS INC$977,0640.27%43,348CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$970,4040.27%425,616CommonSOLE
15673T100IPSCCENTURY THERAPEUTICS INC$952,1540.26%1,704,232CommonSOLE
64135M105NGNENEUROGENE INC$763,8850.21%51,096CommonSOLE
09075V102BNTXBIONTECH SE$745,2900.21%7,000CommonSOLE
M8001Q126PYPDPOLYPID LTD$733,8870.20%207,900CommonSOLE
500946108KRROKORRO BIO INC$720,5610.20%57,691CommonSOLE
M25722105CGENCOMPUGEN LTD$484,8760.13%272,402CommonSOLE
03843E104AQSTAQUESTIVE THERAPEUTICS INC$470,0200.13%142,000CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$448,2190.12%64,492CommonSOLE
29479A108ERASERASCA INC$444,5000.12%350,000CommonSOLE
007002108TORCEURADICET BIO INC$329,4000.09%540,000CommonSOLE
H0036K147ADCTADC THERAPEUTICS SA$327,1770.09%122,081CommonSOLE
869367102STROSUTRO BIOPHARMA INC$312,0310.09%437,079CommonSOLE
640268306NKTRNEKTAR THERAPEUTICS$258,4000.07%10,000CommonSOLE
03836J201APREAPREA THERAPEUTICS INC$231,8240.06%137,174CommonSOLE
09090D301PHGEBIOMX INC$180,5110.05%401,136CommonSOLE
74276L105PRCTPROCEPT BIOROBOTICS CORP$172,8000.05%3,000CommonSOLE
N44821101IFRXINFLARX NV$158,0000.04%200,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.